Article Text

Download PDFPDF
CASE REPORT
Merkel cell carcinoma: an aggressive cutaneous carcinoma with rare metastasis to the thyroid gland
  1. Donata Vaiciunaite,
  2. Gregory Beddell and
  3. Nedyalko Ivanov
  1. Department of GME, Summa Western Reserve Hospital, Cuyahoga Falls, Ohio, USA
  1. Correspondence to Dr Donata Vaiciunaite, dvaiciun{at}gmail.com

Abstract

Merkel cell carcinoma (MCC) is an aggressive and rare neuroendocrine cutaneous carcinoma with poor prognosis and with increasing morbidity and mortality in cases of distant metastasis. Given the rarity of MCC, optimal treatment is not well established. Treatment usually consists of multidisciplinary management with local excision of the primary tumour. Imaging studies are essential for accurate staging and monitoring of disease progression. The incidence of local recurrence is highest in the first 2 years and ranges from 27% to 60%. Distant metastasis is most common in the skin, liver, bone, lung/pleura, brain or distant lymph nodes. The thyroid gland is a rare site of metastasis for MCC with only two case reports published to date. Our patient had a repeat 2-[18F]-fluoro-2-deoxy-d-glucose-postiron emission tomography/CT after the discovery of recurrence of MCC. The high-intensity maximal standardised uptake value of 10.9 in the thyroid isthmus is consistent with malignancy. This case report describes an exceedingly rare thyroid metastasis secondary to MCC.

  • thyroid disease
  • endocrine cancer
  • skin cancer
  • radiology
  • plastic and reconstructive surgery

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors Acquisition of data: DV and GB. Analysis and/or interpretation of data: DV and NI. Drafting the manuscript: DV and NI. Revising the manuscript critically for important intellectual content: DV and GB. Approval of the version of the manuscript to be published: all authors. Agreement to be accountable for the article and to ensure that all questions regarding the accuracy or integrity of the article are investigated and resolved: all authors.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Next of kin consent obtained.